{"disease":{"id":"human-immunodeficiency-virus-infection","name":"Human immunodeficiency virus infection","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":34,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"bictegravir","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Biktarvy","generic_name":"BICTEGRAVIR","company_name":"Gilead Sciences","drug_phase":"marketed","molecular_target":"","drug_class":"Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]","quality_score":70,"revenue":"13400","mechanism":"Biktarvy works by binding to the integrase enzyme, preventing the HIV virus from integrating its genetic material into the host cell's DNA."},{"drug_id":"dolutegravir","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tivicay","generic_name":"DOLUTEGRAVIR","company_name":"GSK","drug_phase":"marketed","molecular_target":"Transmembrane protein 97","drug_class":"Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]","quality_score":72,"revenue":"5200","mechanism":"Tivicay blocks the integrase enzyme, preventing HIV from integrating its genetic material into the host cell's DNA."},{"drug_id":"tenofovir-alafenamide","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vemlidy","generic_name":"TENOFOVIR ALAFENAMIDE","company_name":"Gilead Sciences","drug_phase":"marketed","molecular_target":"","drug_class":"Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]","quality_score":59,"revenue":"2800","mechanism":"Vemlidy works by inhibiting the HIV reverse transcriptase enzyme, preventing viral replication."},{"drug_id":"emtricitabine","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Emtriva","generic_name":"EMTRICITABINE","company_name":"Gilead Sciences","drug_phase":"marketed","molecular_target":"","drug_class":"Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]","quality_score":69,"revenue":"2400","mechanism":"Emtriva works by blocking the reverse transcriptase enzyme, which is necessary for HIV to replicate."},{"drug_id":"cabotegravir","indication_name":"Human immunodeficiency virus I infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vocabria","generic_name":"CABOTEGRAVIR","company_name":"GSK","drug_phase":"marketed","molecular_target":"","drug_class":"Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor","quality_score":60,"revenue":"2100","mechanism":"Vocabria works by blocking the integrase enzyme, which is necessary for the virus to replicate."},{"drug_id":"delavirdine","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rescriptor","generic_name":"DELAVIRDINE","company_name":"GSK","drug_phase":"marketed","molecular_target":"Histamine H4 receptor","drug_class":"Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor","quality_score":33,"revenue":null,"mechanism":""},{"drug_id":"abacavir","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ziagen","generic_name":"ABACAVIR","company_name":"GSK","drug_phase":"marketed","molecular_target":"","drug_class":"Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor","quality_score":60,"revenue":null,"mechanism":"Abacavir works by mimicking a building block of DNA, tricking the virus into incorporating it into its genetic material and preventing replication."},{"drug_id":"efavirenz","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sustiva","generic_name":"EFAVIRENZ","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Cholesterol 24-hydroxylase","drug_class":"Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]","quality_score":60,"revenue":null,"mechanism":"Sustiva works by binding to the reverse transcriptase enzyme, preventing the replication of viral RNA."},{"drug_id":"lamivudine","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Epivir","generic_name":"LAMIVUDINE","company_name":"GSK","drug_phase":"marketed","molecular_target":"Deoxycytidine kinase","drug_class":"Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]","quality_score":66,"revenue":null,"mechanism":"Epivir works by mimicking the building blocks of DNA to prevent the replication of viral genetic material."},{"drug_id":"indinavir","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Crixivan","generic_name":"INDINAVIR","company_name":"Merck & Co.","drug_phase":"discontinued","molecular_target":"Cytochrome P450 3A4","drug_class":"indinavir","quality_score":0,"revenue":null,"mechanism":"Crixivan blocks the replication of HIV by inhibiting the protease enzyme, which is essential for the virus to produce new particles."},{"drug_id":"cobicistat","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tybost","generic_name":"COBICISTAT","company_name":"Gilead Sciences","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A","drug_class":"Cytochrome P450 3A Inhibitor [EPC]","quality_score":50,"revenue":null,"mechanism":"Tybost works by blocking the enzyme Cytochrome P450 3A, which is responsible for breaking down many other medications."},{"drug_id":"etravirine","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Intelence","generic_name":"ETRAVIRINE","company_name":"Janssen R And D","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 2","drug_class":"Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]","quality_score":53,"revenue":null,"mechanism":"Intelence works by blocking the reverse transcriptase enzyme, which is essential for the replication of the HIV virus."},{"drug_id":"elvitegravir","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vitekta","generic_name":"ELVITEGRAVIR","company_name":"Gilead Sciences","drug_phase":"marketed","molecular_target":"","drug_class":"Cytochrome P450 3A Inhibitor [EPC]","quality_score":50,"revenue":null,"mechanism":"Vitekta blocks the integrase enzyme, preventing HIV from replicating."},{"drug_id":"raltegravir-use-ral-as-a-simplification-strategy","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Raltegravir (Use RAL as a simplification strategy)","company_name":"Hospital Carlos III, Madrid","drug_phase":"marketed","molecular_target":"C-C chemokine receptor type 1, Gag-Pol polyprotein, Integrase","drug_class":"Integrase inhibitors","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"zidovudine","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Retrovir","generic_name":"ZIDOVUDINE","company_name":"GSK","drug_phase":"marketed","molecular_target":"Thymidine kinase, cytosolic","drug_class":"Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]","quality_score":75,"revenue":null,"mechanism":"Retrovir works by mimicking the natural building blocks of DNA to prevent HIV from replicating."},{"drug_id":"fuzeon","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fuzeon","company_name":"Trimeris","drug_phase":"phase_1","molecular_target":"Envelope glycoprotein, GP41, Transmembrane glycoprotein gp41","drug_class":"","quality_score":12,"revenue":null,"mechanism":""},{"drug_id":"fosamprenavir","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lexiva","generic_name":"FOSAMPRENAVIR","company_name":"GSK","drug_phase":"marketed","molecular_target":"","drug_class":"Protease Inhibitor","quality_score":56,"revenue":null,"mechanism":"Lexiva works by blocking the protease enzyme, which is necessary for HIV to replicate."},{"drug_id":"viread","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Viread","company_name":"Replicor Inc.","drug_phase":"marketed","molecular_target":"Gag-Pol polyprotein, Reverse transcriptase/RNaseH","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"tesamorelin-acetate","indication_name":"Lipodystrophy due to Human immunodeficiency virus infection and antiretroviral therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Egrifta","generic_name":"TESAMORELIN ACETATE","company_name":"Theratechnologies","drug_phase":"marketed","molecular_target":"Growth hormone-releasing hormone receptor","drug_class":"Growth Hormone Releasing Factor Analog","quality_score":10,"revenue":null,"mechanism":"Egrifta works by mimicking the action of growth hormone-releasing hormone to stimulate the release of growth hormone."},{"drug_id":"amprenavir","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Agenerase","generic_name":"AMPRENAVIR","company_name":"GSK","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"Protease Inhibitor","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"ritonavir","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norvir","generic_name":"ritonavir","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C9","drug_class":"Cytochrome P450 3A Inhibitor [EPC]","quality_score":80,"revenue":null,"mechanism":"Norvir works by blocking the cytochrome P450 3A enzyme, which helps increase the levels of other medications in the body."},{"drug_id":"didanosine","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Videx","generic_name":"DIDANOSINE","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"","drug_class":"Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"nelfinavir","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Viracept","generic_name":"NELFINAVIR","company_name":"Agouron Pharms","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"Protease Inhibitor","quality_score":65,"revenue":null,"mechanism":"Viracept works by blocking the protease enzyme, which is essential for the replication of HIV."},{"drug_id":"atazanavir","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Reyataz","generic_name":"ATAZANAVIR","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"UDP-glucuronosyltransferase 1-1","drug_class":"Protease Inhibitor","quality_score":75,"revenue":null,"mechanism":"Reyataz works by blocking the protease enzyme, which is essential for the replication of HIV."},{"drug_id":"lopinavir","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kaletra","generic_name":"LOPINAVIR","company_name":"Abbvie Deutschland Gmbh Co. Kg","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2","drug_class":"Cytochrome P450 3A Inhibitor [EPC]","quality_score":65,"revenue":null,"mechanism":"Kaletra blocks the protease enzyme, preventing the HIV virus from replicating."},{"drug_id":"nevirapine","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Viramune","generic_name":"NEVIRAPINE","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"","drug_class":"Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]","quality_score":70,"revenue":null,"mechanism":"Viramune works by binding to the reverse transcriptase enzyme, preventing HIV from replicating."},{"drug_id":"enfuvirtide","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fuzeon","generic_name":"ENFUVIRTIDE","company_name":"Roche","drug_phase":"marketed","molecular_target":"","drug_class":"Human Immunodeficiency Virus 1 Fusion Inhibitor","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"doravirine","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pifeltro","generic_name":"DORAVIRINE","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"","drug_class":"Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]","quality_score":60,"revenue":null,"mechanism":"Pifeltro works by blocking the reverse transcriptase enzyme, which is essential for the replication of the HIV virus."},{"drug_id":"norvir","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Norvir","company_name":"Saint Michael's Medical Center","drug_phase":"marketed","molecular_target":"UDP-glucuronosyltransferase 1-1, Cytochrome P450 2C9, Multidrug and toxin extrusion protein 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"rescriptor","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Rescriptor","company_name":"Pfizer","drug_phase":"phase_2","molecular_target":"Malate dehydrogenase cytoplasmic , ATP-binding cassette sub-family G member 2, Histamine H4 receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"sustiva","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Sustiva","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Cholesterol 24-hydroxylase, ATP-binding cassette sub-family G member 2, Nuclear receptor subfamily 1 group I member 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"tivicay","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Tivicay","company_name":"St Stephens Aids Trust","drug_phase":"marketed","molecular_target":"Transmembrane protein 97, Integrase, Integrase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"viramune","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Viramune","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Gag-Pol polyprotein, Pol polyprotein, Reverse transcriptase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ibalizumab","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trogarzo","generic_name":"IBALIZUMAB","company_name":"Taimed Biologics Usa","drug_phase":"marketed","molecular_target":"T-cell surface glycoprotein CD4","drug_class":"CD4-directed Blocking Antibody [EPC]","quality_score":48,"revenue":null,"mechanism":"Trogarzo works by binding to the CD4 receptor on T-cells, preventing HIV from entering and infecting these cells."},{"drug_id":"fostemsavir","indication_name":"Human immunodeficiency virus I infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rukobia","generic_name":"FOSTEMSAVIR","company_name":"GSK","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"","quality_score":51,"revenue":null,"mechanism":"Rukobia works by blocking the potassium voltage-gated channel subfamily H member 2, which is involved in the replication of the human immunodeficiency virus 1."},{"drug_id":"darunavir","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prezista","generic_name":"DARUNAVIR","company_name":"Janssen Prods","drug_phase":"marketed","molecular_target":"Multidrug resistance protein 1","drug_class":"Protease Inhibitor [EPC]","quality_score":62,"revenue":null,"mechanism":"Darunavir works by blocking the protease enzyme, which is essential for the replication of the HIV virus."},{"drug_id":"invirase","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Invirase","company_name":"Saint Michael's Medical Center","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, ATP-binding cassette sub-family G member 2, Multidrug resistance protein 1","drug_class":"","quality_score":16,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":37,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06368453","title":"A Study to Evaluate the Performance, Usability, and Result Interpretation of INSTI® HIV Self-Test","phase":"NA","overall_status":"COMPLETED","enrollment_count":1728,"lead_sponsor_name":"bioLytical Laboratories","has_results":false},{"nct_id":"NCT05031819","title":"Managing Hypertension Among People Living With HIV","phase":"NA","overall_status":"COMPLETED","enrollment_count":960,"lead_sponsor_name":"Dr. Dike Ojji","has_results":false},{"nct_id":"NCT04772469","title":"Self-Test Strategies and Linkage Incentives to Improve ART and PrEP Uptake in Men","phase":"NA","overall_status":"COMPLETED","enrollment_count":934,"lead_sponsor_name":"University of California, San Francisco","has_results":true},{"nct_id":"NCT03618511","title":"Interventions to Improve HIV Antiretroviral Therapy Adherence","phase":"NA","overall_status":"COMPLETED","enrollment_count":914,"lead_sponsor_name":"University of Michigan","has_results":false},{"nct_id":"NCT01231516","title":"A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":724,"lead_sponsor_name":"ViiV Healthcare","has_results":true},{"nct_id":"NCT02831764","title":"An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":722,"lead_sponsor_name":"ViiV Healthcare","has_results":true},{"nct_id":"NCT02831673","title":"An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":719,"lead_sponsor_name":"ViiV Healthcare","has_results":true},{"nct_id":"NCT02965014","title":"NC Young Women's CoOp","phase":"NA","overall_status":"TERMINATED","enrollment_count":652,"lead_sponsor_name":"RTI International","has_results":false},{"nct_id":"NCT02951052","title":"Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":618,"lead_sponsor_name":"ViiV Healthcare","has_results":true},{"nct_id":"NCT05452616","title":"Same-day Versus Rapid ART Initiation in HIV-positive Individuals Presenting With Symptoms of Tuberculosis","phase":"NA","overall_status":"COMPLETED","enrollment_count":610,"lead_sponsor_name":"University Hospital, Basel, Switzerland","has_results":false},{"nct_id":"NCT03310515","title":"Incidence of Human Immunodeficiency Virus-1 (HIV-1) Infection in HIV-1 Uninfected High Risk Men Who Have Sex With Men","phase":"","overall_status":"COMPLETED","enrollment_count":578,"lead_sponsor_name":"ViiV Healthcare","has_results":false},{"nct_id":"NCT07266831","title":"A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":570,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT01910402","title":"A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":499,"lead_sponsor_name":"ViiV Healthcare","has_results":true},{"nct_id":"NCT01709084","title":"A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":426,"lead_sponsor_name":"Janssen-Cilag International NV","has_results":true},{"nct_id":"NCT07209917","title":"Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India","phase":"NA","overall_status":"RECRUITING","enrollment_count":420,"lead_sponsor_name":"University of California, Irvine","has_results":false},{"nct_id":"NCT05769413","title":"Awareness of Osteoporosis in HIV Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":400,"lead_sponsor_name":"Uskudar State Hospital","has_results":false},{"nct_id":"NCT07039682","title":"Empowering Knowledge, Self-Testing & Resilience Through Innovative Methods for HIV","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":400,"lead_sponsor_name":"Universitas Sebelas Maret","has_results":false},{"nct_id":"NCT04191967","title":"Thermocoagulation for Treatment of Precancerous Cervical Lesions","phase":"NA","overall_status":"COMPLETED","enrollment_count":379,"lead_sponsor_name":"University of California, San Francisco","has_results":true},{"nct_id":"NCT01939197","title":"A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":318,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT02120352","title":"A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":309,"lead_sponsor_name":"ViiV Healthcare","has_results":true},{"nct_id":"NCT04768517","title":"HCV Reinfection in in HIV/HCV-coinfected Patients Achieving SVR by Antiviral Therapy","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT06886971","title":"Strategies to AchieVe Viral Suppression for Youth With HIV","phase":"NA","overall_status":"RECRUITING","enrollment_count":288,"lead_sponsor_name":"Johns Hopkins University","has_results":false},{"nct_id":"NCT01448707","title":"A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":274,"lead_sponsor_name":"Janssen-Cilag International NV","has_results":true},{"nct_id":"NCT07370649","title":"Long-Acting Cabotegravir and Rilpivirine in People Living With HIV-1 Subtype A6: A Real-World Retrospective Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":250,"lead_sponsor_name":"Pomeranian Medical University Szczecin","has_results":false},{"nct_id":"NCT01641809","title":"Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":244,"lead_sponsor_name":"ViiV Healthcare","has_results":true},{"nct_id":"NCT00046176","title":"A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":240,"lead_sponsor_name":"ViiV Healthcare","has_results":false},{"nct_id":"NCT03800407","title":"Contributing Factors for Poor HIV Treatment Response in Children With TB/HIV Coinfection","phase":"","overall_status":"COMPLETED","enrollment_count":213,"lead_sponsor_name":"University of Florida","has_results":false},{"nct_id":"NCT07476339","title":"REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"CAN Community Health","has_results":false},{"nct_id":"NCT01536873","title":"Dolutegravir Expanded Access Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"ViiV Healthcare","has_results":false},{"nct_id":"NCT03284645","title":"Viral and Antiretroviral Dynamics in HIV-1 Mother-to-Child Transmission Fluids","phase":"","overall_status":"COMPLETED","enrollment_count":194,"lead_sponsor_name":"Obafemi Awolowo University","has_results":false},{"nct_id":"NCT00044577","title":"New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":166,"lead_sponsor_name":"ViiV Healthcare","has_results":false},{"nct_id":"NCT02738138","title":"A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":153,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT06891066","title":"A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":150,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT02103439","title":"An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":140,"lead_sponsor_name":"Biocad","has_results":true},{"nct_id":"NCT03101644","title":"Optimization of Darunavir Therapy and Dosage Recommendations","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":127,"lead_sponsor_name":"Université Catholique de Louvain","has_results":false},{"nct_id":"NCT07061912","title":"A Study to Evaluate the Performance of INSTI® HIV Self Test When Performed by Unobserved Intended Users in the US","phase":"NA","overall_status":"COMPLETED","enrollment_count":122,"lead_sponsor_name":"bioLytical Laboratories","has_results":false},{"nct_id":"NCT02741557","title":"Bioequivalence Study of a Fixed-dose Combination (FDC) of Dolutegravir (DTG) and Rilpivirine (RPV)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":118,"lead_sponsor_name":"ViiV Healthcare","has_results":false},{"nct_id":"NCT02178592","title":"Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":113,"lead_sponsor_name":"ViiV Healthcare","has_results":true},{"nct_id":"NCT01803074","title":"Study to Evaluate a HIV Drug for the Treatment of HIV Infection","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":107,"lead_sponsor_name":"ViiV Healthcare","has_results":true},{"nct_id":"NCT02479698","title":"Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03729778","title":"Impact of HIV-1 and Aging on Mucosal Vaccine Responses","phase":"EARLY_PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":100,"lead_sponsor_name":"VA Eastern Colorado Health Care System","has_results":false},{"nct_id":"NCT05372510","title":"Feasibility of Identifying, Enrolling and Following Acute and Early HIV-1 Infected Individuals.","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"MRC/UVRI and LSHTM Uganda Research Unit","has_results":false},{"nct_id":"NCT03800381","title":"Adequacy of the New Pediatric Isoniazid/Rifampin/Pyrazinamide (HRZ) Tablet","phase":"","overall_status":"COMPLETED","enrollment_count":92,"lead_sponsor_name":"University of Florida","has_results":false},{"nct_id":"NCT04375800","title":"Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":84,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT05065905","title":"Study of Interferon-Gamma in the Complex Treatment of Patients Infected With HIV and Tuberculosis","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":78,"lead_sponsor_name":"SPP Pharmaclon Ltd.","has_results":true},{"nct_id":"NCT03231943","title":"GSK3640254 First Time in Human (FTIH) Study in Healthy Volunteers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":78,"lead_sponsor_name":"ViiV Healthcare","has_results":true},{"nct_id":"NCT05328583","title":"A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral HRS5685 in Healthy Subjects","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":64,"lead_sponsor_name":"RetroLead (Shanghai) BioPharma Co., Ltd.","has_results":false},{"nct_id":"NCT00071760","title":"Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":59,"lead_sponsor_name":"ViiV Healthcare","has_results":true},{"nct_id":"NCT03563742","title":"A Study to Determine the Safety and Efficacy of Rilpivirine in Treatment-naive Indian Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":58,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT02817451","title":"DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected Infants","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":53,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":false}],"total":50},"guidelines":[{"drug_id":"bictegravir","guideline_body":"FDA label","recommendation":"BIKTARVY is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 14 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no known or suspected substitutions associated with resistance to bictegravir or tenofovir.","line_of_therapy":"1L|2L","evidence_grade":"A","guideline_year":null},{"drug_id":"ritonavir","guideline_body":"FDA label","recommendation":"Lopinavir and ritonavir is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 14 days and older.","line_of_therapy":"any","evidence_grade":"A","guideline_year":null}],"source":"Drug Landscape verified database"}